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Human metapneumovirus (hMPV) is genetically related to respiratory syncytial virus (RSV); both
cause respiratory tract illnesses ranging from a mild cough to bronchiolitis and pneumonia. The F
protein-directed monoclonal antibody (mAb) palivizumab has been shown to prevent severe lower
respiratory tract RSV infection in animals and humans. We have previously reported on a panel of
mAbs against the hMPV F protein that neutralize hMPV in vitro and, in two cases, in vivo. Here we
describe the generation of hMPV mAb-resistant mutants (MARMs) to these neutralizing
antibodies. Sequencing the F proteins of the hMPV MARMs identified several neutralizing
epitopes. Interestingly, some of the epitopes mapped on the hMPV F protein coincide with
homologous regions mapped previously on the RSV F protein, including the site against which the
broadly protective mAb palivizumab is directed. This suggests that these homologous regions play
important, conserved functions in both viruses.
Human metapneumonovirus (hMPV) is a recently described
pathogenic respiratory paramyxovirus, with a disease
pathology most similar to human respiratory syncytial virus
(RSV). Both cause illness ranging from mild respiratory
distress to bronchiolitis and pneumonia (van den Hoogen
et al., 2001; Williams et al., 2006). RSV and hMPV have been
subdivided into A and B subgroups based upon sequence
diversity among isolates, and hMPV has been further
dissected into sublineages denoted A1, A2, B1 and B2
(Peret et al., 2002; van den Hoogen et al., 2004). Like all
paramyxoviruses, hMPV expresses a core group of genes,
including three intrinsic membrane proteins: the fusion
glycoprotein (F), attachment glycoprotein (G) and small
hydrophobic protein (van den Hoogen et al., 2002; Easton
et al., 2004). Viral coat proteins are prime targets for
neutralizing antibodies and have been shown to elicit
protective immunity in animal models. However, studies
ontheindividualcontributions ofthe hMPVcoatproteinsto
the production of protective immunity showed that only the
highly conserved F protein elicited a high-titre neutralizing
antibody response (Skiadopoulos et al., 2006). F protein
immunization in varied formats induced protective immun-
ity, in some instances protecting against subsequent
challenge with a heterologous strain of hMPV (MacPhail
et al., 2004; Tang et al., 2005; Ma et al., 2005; Skiadopoulos
et al., 2004; Cseke et al., 2007; Herfst et al., 2007).
The ability of F-protein-directed monoclonal antibodies
(mAbs) to neutralize RSV both in vitro and in vivo is well
established (Johnson et al., 1997; Wu et al., 2005), perhaps
best validated by the clinical use of the anti-RSV F mAb
palivizumab as a prophylactic to reduce RSV disease in
at-risk infants (Impact-RSV Study Group, 1998). The
characteristics that make RSV F protein a good target for a
broadly protective mAb are shared by hMPV F protein; we
recently reported on a panel of 12 mAbs specific for hMPV
F protein that effectively neutralized some or all hMPV
sublineages either in vitro or in vivo (Ulbrandt et al., 2006).
These antibodies were classified into six groups based upon
their ability to neutralize the four hMPV sublineage
prototypes and to compete for binding to recombinant
hMPV F protein.
To extend our knowledge of the hMPV F protein antigenic
structure, mAb-resistant mutants (MARMs) were gener-
ated to nine of the 12 neutralizing mAbs reported by
Ulbrandt et al. (2006). These mAbs spanned five of the six
epitope groups that we had identified previously; we were
unable to select MARMs against the group 1 mAb. To
generate MARMs, virus isolates NL\1\00 (hMPV sublin-
eage A1) or NL\1\99 (hMPV sublineage B1) at concentra-
tions between 0.1610
6 and 5610
6 TCID50 were passaged
in the presence of 50 times the IC50 of the antibodies in 24-
well plates (the choice of virus sublineage was determined
by its sensitivity to the mAb used for selection). For each
mAb, 20–100 wells were scored for infection, in which 1–8
wells were positive for viral antigen production. Each
individual positive well was passaged an additional two
times in 50 times the IC50 of selection mAb. As hMPV does
not form plaques or show substantial cytopathic effects in
Vero cells, clonal isolation of the resistant mutants was not
attempted with the expectation that individual positive
wells would result from a limited number of viral particles.
Following isolation, the viruses were retested for neutral-
ization by the selection antibody, and in all cases they
retained their resistance in a standard microneutralization
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MARMs was performed as follows: each of the MARM virus
preparations and the wild-type viral strains used to produce
theMARMs(NL\1\00andNL\1\99)wasincubatedwitheach
of the antibodies (100, 10 or 1 mgm l
21). The MARM was
considered resistant if it was not neutralized at a mAb
concentration 10-fold above the IC50 for wild-type virus. The
ability of the panel of mAbs toneutralize single isolates of the
MARMs was then determined (Table 1). Much of the data
from these experiments concur with the data collected
previously from a competitive hMPV F protein binding
ELISA (Ulbrandt et al., 2006). For example, mAb 757, which
did not compete with any other antibody in the ELISA,
effectivelyneutralizedalltheMARMsisolatedusingtheother
antibodies and all other antibodies neutralized the mAb 757
MARM.
We next determined the sequences of the F protein gene for
all the isolated MARMs. RNA was extracted from infected
cells using the RNAeasy kit (Qiagen). cDNA was made using
random primers with the You-Prime-It cDNA kit (GE
Healthcare). The cDNA was used in a PCR to isolate the
soluble portion of the F protein using the following primers:
NL\1\00 59 primer (59-GGATCCCCTTAAAGAGAGCTAC-
TTAGAAGAG-39)a n d3 9 primer (59-GAATTCTTAGCCA-
GTGTTTCCTTTCTCTGC-39)o rN L \ 1 \ 9 95 9 primer
(59-GGATCCCCTAAAGGAGAGTTATTTGGAAG-39)a n d
the NL\1\00 39 primer. PCR products were sequenced using
ABIBigDyedyeterminatorv3.1andwereanalysedonanABI
DNA analyser.
The sequences of the F protein were compared to the
sequences of the input virus used for selection, as well as to
virus passaged in the presence of an irrelevant mAb. In
many cases, the same mutations were found in multiple
isolates; however, each individual mutation is shown only
once in Table 2. MARMs used for the cross-neutralization
studies are italicized and underlined. Epitope group 2
MARMs derived from mAb 757 were sequenced and found
to have mutations at aa 132 and 152 (Table 2). This region
is in the first heptad repeat of the hMPV F protein (a
schematic of the domain structure and MARM mutation
sites of hMPV and RSV F protein is provided in Fig. 1) and
although the mutations are not close in primary sequence,
this region is predicted to form an extended a-helix (post-
fusion) and aa 132 and 152 might present on the same face
of this helix.
F protein mutations in MARMs generated against the
epitope group 3 antibody pair, mAbs 967 and 1025, map to
a region between aa 177 and 179 (Table 2). Aa position 179
is one (of only three) that discriminates the B1 F protein
sequence from all other hMPV sublineages; arginine in the
B1 prototype NL\1\99, lysine in all others. The group 3
mAbs have no neutralizing efficacy against NL\1\99, and
NL\1\00 MARMs generated against the group 3 mAbs
contained a lysine to arginine change at this position. The
other mutations at this position resulted in either a change
in charge or the addition of a bulkier side group, suggesting
that aa 179 makes direct contact with a complementarity-
determining region on the group 3 mAbs; the mutation at
position 178 may alter how aa 179 is disposed in the folded
structure.
The epitope group 4 antibodies, of which mAbs 234 and
338 have been shown to protect against challenge with both
A1 and B1 sublineages of hMPV in vivo, required high
levels of virus in order to isolate a small number of escape
mutants. The MARMs derived from selection with mAbs
338 and 234 were resistant to all three antibodies in group
4, but MARMs selected against mAb 628 selection were
only resistant to mAb 628 (Table 1). Sequence analysis of
Table 1. Cross-neutralization analysis of MARMs
R, indicates the MARMs that were resistant to neutralization with the antibody listed. MARMs were not generated against mAbs 242 and 344.
Antibody used for selection
Group 2 Group 3 Group 4 Group 5 Group 6
Antibody tested mAb
757
mAb
967
mAb
1025
mAb
234
mAb
338
mAb
628
mAb
659
mAb
710
mAb
836
Group 2 mAb 757 R
Group 3 mAb 967 RR
mAb 1025 RR
Group 4 mAb 234 RR
mAb 338 RR
mAb 628 RRR
Group 5 mAb 344 RR
mAb 659 R
mAb 710 RR
Group 6 mAb 242 RR
mAb 836 RR
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neutralization assays, in that all three antibodies selected
for mutations in the same region of the F protein but the
mutations isolated by selection with mAb 628 were
different to the mutations found in the mAb 338 and 234
MARMs. This suggests that the binding site of mAb 628 is
different but adjacent to the mAb 234 and 338 binding
sites, in agreement with competition ELISA results.
The epitope group 5 and 6 MARMs were sequenced and
mutations were found to map to position 386–397 of the
hMPV F protein (Table 2). The location of these mutations
confirms that mAbs 710 and 836 bind to the same region.
The mutations in the F protein isolated by selection with
mAb 659 were proximal to the mAb 710 and 836
mutations but did not confer resistance to all of the other
antibodies in these groups (Table 1). In addition, the
Table 2. Amino acid variations in hMPV MARMs
The italicized mutations are those that were used in generating the cross-neutralization data in Table 1.
Strain Selection Epitope
group
Aa
132 152 177 178 179 238 239 241 242 245 386 397
NL\1\99 Control IgG SGINR A G I K LK V
MARMs mAb 757 2 R
R
mAb 659 5/6 E
mAb 710 5/6 F
mAb 836 5/6 F
NL\1\00 Control IgG SGINK A G I K LK W
MARMs mAb 967 3 E
N
R
mAb 1025 3 Y
E
VR
mAb 234 4 N
mAb 338 4 R
N
EN
TN
ET
mAb 628 4 ES
ES
E
E
Fig. 1. Schematic depiction of hMPV and
RSV F protein domain structures and relative
location of MARM mutation sites. Indicated are
the N terminus (N), signal peptide (SP), fusion
peptide (FP), heptad repeat 1 (HR1), heptad
repeat 2 (HR2), transmembrane domain (TM)
and C terminus (C), as well as the F1 and F2
segments of the F protein. The amino acid
positions that border domains (predicted) or
cleavage sites and C termini (known) are
indicated. Also depicted are the relative posi-
tions of the hMPV epitope group MARM
mutations and corresponding MARM mutation
sites on the RSV F protein (see text for details).
Neutralizing epitopes on hMPV F protein
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differences between the A1, A2 and B2 prototypes at
position 396, providing (as above for the group 3 mAbs) a
possible explanation for the different sensitivities of the
hMPV sublineages to the group 5 and 6 mAbs.
The characterization of resistant mutants is one of the
primary tools of virus structure/function research. Our work
on hMPV, both in developing neutralizing antibodies and in
generating MARMs, has been informed by the instructive
experience of ourselves and others with RSV. The antigenic
structure of RSV F protein has been defined in a number of
ways. First, panels of antibodies were generated against RSV
Fproteinandthesewereclassifiedintodifferentgroupsbased
on their ability to bind different RSV strains or to compete
for binding to the same strain (e.g. Beeler & van Wyke
Coelingh, 1989). The physical antibody binding sites on the
RSV F protein were primarily determined in two ways. In
some cases, the antibodies bound to peptide segments of the
target antigen (e.g. Lopez et al., 1993; Lounsbach et al.,1 9 9 3 ;
Langedijk et al., 1998) or MARMs were selected and the
locations of the amino acid changes on the RSV F protein
that conferred resistance were identified (e.g. Arbiza et al.,
1992; Crowe etal., 1998; Lopez etal., 1998;Zhao etal., 2004).
The combination of the competition, cross-neutralization/
binding, peptide binding and MARM mutational data has
provided a fairly detailed picture of the functional domain
architecture of the RSV F protein.
A schematic depiction of RSV F protein domain structure is
illustrated on the lower half of Fig. 1, with the approximate
location of the primary immunogenic sites along the linear
sequence indicated. The A site was first delineated by Beeler
& van Wyke Coelingh (1989) and the antigenic areas I–VI
were classified by Melero and co-workers (Arbiza et al.,1 9 9 2 ;
Lopez et al., 1998). The homologous domain structure of the
hMPV F protein is indicated on the upper half of Fig. 1; the
alignment of hMPV and RSV F protein structures is based
both on amino acid sequence comparison (which only
averages ~33% sequence identity between hMPV and RSV
subgroups) and on the predicted locations and boundaries of
functional domains. The relative location of the amino acid
changes associated with the MARMs that were selected by
our panel of anti-hMPV F protein mAbs indicate that some
of these mutational hotspots share common locations on
both RSV and hMPV F protein.
The epitope group 2 MARMs localize to two amino acid
positions (132 and 152) within the predicted heptad repeat
1 of hMPV F protein. No RSV MARMs that localize to this
region have been reported, but a neutralizing mAb
generated against bovine RSV F protein has been suggested
to bind to this region (Langedijk et al., 1998). Similarly, no
RSV MARMs have been mapped to the region homologous
to epitope group 3 on hMPV F protein, but neutralizing
mAbs have been generated against a peptide that spans a
corresponding region of RSV F protein (Corvaisier et al.,
1997). Finally, epitope groups 5 and 6 map to a
neutralizing antigenic region on hMPV F protein which
overlaps antigenic region IV and is slightly N-terminal to
the antigenic regions V and VI on RSV F protein (Arbiza
et al., 1992; Lopez et al., 1998).
From a clinical perspective, the epitope group 4 mAbs 234
and 338 are the most interesting, as these mAbs neutralize
prototypic hMPV A1 and B1 viruses both in vitro and in vivo
(Ulbrandt et al., 2006). Of note, the site that these mAbs
recognizeon the hMPV F proteincorresponds to the cognate
A site or siteIIdefinedforRSV F protein(Beeler& van Wyke
Coelingh, 1989; Arbiza et al., 1992) that is recognized by the
neutralizing anti-RSV monoclonal palivizumab, which is
effective at reducing RSV disease in humans (Impact-RSV
Study Group, 1998). mAbs to epitope 4 of hMPV F protein
target the most conserved epitope found in all sublineages of
hMPV. AswithRSV, thisregionprobablyplays animportant
role in the virus and may only tolerate minor changes. Based
on the experience with palivizumab and RSV disease, this
suggests that mAbs to this region in hMPV F protein could
have clinical potential.
ThemechanismbywhichFprotein-directedmAbsneutralize
virus (either hMPV or RSV) is still unresolved. Steric
blockage may be involved, but a more likely mechanism of
action would involve binding to a ‘pre-fusion’ conformation
of the F protein and inhibiting the hairpin formation
between the first and second heptad repeats currently
modelled to bring the viral and target cell membranes into
apposition and subsequent fusion (Zhao et al.,2 0 0 0 ;L a m bet
al., 2006; Miller et al., 2007). These models suggest that mAb
neutralization could involve binding to sites in the F protein
important to this conformational transition. These could be
binding either initially distal sites which must come into
proximity or regions which serve as a hinge, or simply by
stabilizing the pre-fusion conformation in some way. As
previouslyreported(Ulbrandtetal., 2006), the epitope group
6 mAbs compete for binding with the epitope group 4 mAbs,
even though the mutations associated with their particular
MARMs are ~150 aa apart in the primary sequence. This
suggests that these epitopes are adjacent in the folded three-
dimensional structure, in agreement with homology mod-
elling of the hMPV F protein based on the structures of
Newcastle disease virus (Smith et al., 2002) and human
parainfluenza virus (Morton et al., 2003) F proteins.
A final point of note is the low number of broadly
neutralizing mAbs we derived that are directed against
hMPV F protein. Due to the high degree of conservation of
the F protein, it is somewhat surprising that more of the
neutralizing antibodies were not pan-specific. Throughout
the extra-membranous region of the hMPV F protein
(roughly 450 aa in length) there are only 25 positions that
vary within and between sublineages. The observation that
variations occur in only ~6% of the amino acids in the
extra-membranous region of hMPV suggests that most of
the amino acid positions in the F protein are crucial to its
function. In conclusion, our studies emphasize the
structural and functional similarities of the fusion proteins
of RSV and hMPV.
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